Literature DB >> 15635635

The design of a new potent and selective ligand for the orphan bombesin receptor subtype 3 (BRS3).

Robert G Boyle1, John Humphries, Tim Mitchell, Graham A Showell, Robert Apaya, Hiroaki Iijima, Hiroshi Shimada, Tomonori Arai, Hiroaki Ueno, Yoshihiro Usui, Toshiro Sakaki, Etsuko Wada, Keiji Wada.   

Abstract

Extensive SAR studies on the unselective BRS3 agonist, [H-D-Phe6,beta-Ala11,Phe13,Nle14]-bombesin-(6-14)-nonapeptide amide, have highlighted structural features important for BRS3 activity and have provided guidance as to the design of selective agonists. A radically modified heptapeptide agonist, maintaining only the Trp-Ala moiety of the parent [H-D-Phe6,betaAla11,Phe13,Nle14]-peptide amide, and with a very different carboxyl terminal region, has been produced which was potent at BRS3 and essentially had no NMB or GRP receptor activity. Its structure is Ac-Phe-Trp-Ala-His(tauBzl)-Nip-Gly-Arg-NH2. Copyright (c) 2004 European Peptide Society and John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15635635     DOI: 10.1002/psc.599

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  10 in total

1.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

Review 2.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

3.  Development and Characterization of a Novel, High-Affinity, Specific, Radiolabeled Ligand for BRS-3 Receptors.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

4.  Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.

Authors:  Iyassu K Sebhat; Christopher Franklin; Michael M-C Lo; David Chen; James P Jewell; Randy Miller; Jianmei Pang; Oksana Palyha; Yanqing Kan; Theresa M Kelly; Xiao-Ming Guan; Donald J Marsh; Jennifer A Kosinski; Joseph M Metzger; Kathryn Lyons; Jasminka Dragovic; Peter R Guzzo; Alan J Henderson; Marc L Reitman; Ravi P Nargund; Matthew J Wyvratt; Linus S Lin
Journal:  ACS Med Chem Lett       Date:  2010-10-18       Impact factor: 4.345

5.  Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.

Authors:  Terry W Moody; Veronica Sancho; Alessia di Florio; Bernardo Nuche-Berenguer; Samuel Mantey; Robert T Jensen
Journal:  Peptides       Date:  2011-06-25       Impact factor: 3.750

6.  Activation of bombesin receptor subtype-3 influences activity of orexin neurons by both direct and indirect pathways.

Authors:  Naoki Furutani; Mari Hondo; Natsuko Tsujino; Takeshi Sakurai
Journal:  J Mol Neurosci       Date:  2010-05-14       Impact factor: 3.444

7.  Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.

Authors:  Nieves Gonzalez; Simon J Hocart; Sergio Portal-Nuñez; Samuel A Mantey; Tomoo Nakagawa; Enrique Zudaire; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2007-11-15       Impact factor: 4.030

Review 8.  Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states.

Authors:  Nieves Gonzalez; Terry W Moody; Hisato Igarashi; Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-02       Impact factor: 3.243

Review 9.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

10.  Constitutively active BRS3 is a genuinely orphan GPCR in placental mammals.

Authors:  Huihao Tang; Chuanjun Shu; Haidi Chen; Xiaojing Zhang; Zhuqing Zang; Cheng Deng
Journal:  PLoS Biol       Date:  2019-03-06       Impact factor: 8.029

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.